Combined effects of single nucleotide polymorphisms TP53 R72P and MDM2 SNP309, and p53 expression on survival of breast cancer patients

Table 6 HR estimates of multivariate analyses for MDM2 SNP309 stratified by TP53 R72P

	HR	Lower and upper limit 95% CI		Pvalue	HR	Lower and upper limit 95% CI		Pvalue	HR	Lower and upper limit 95% CI		Pvalue
	TP53R72P: GG				TP53R72P: GC				TP53R72P: CC
*MDM2* SNP309 TT	1.0 (Ref)				1.0 (Ref)				1.0 (Ref)
TG	.90	.73	1.11	.33	.94	.73	1.20	.61	.85	.47	1.55	.60
GG	.85	.63	1.16	.31	1.43	1.05	1.96	.02	1.39	.56	3.48	.48
p53 negative	1.0 (Ref)				1.0 (Ref)				1.0 (Ref)
positive	1.37	.96	1.96	.08	.89	.58	1.35	.57	.76	.25	2.30	.63
missing	1.63	1.16	2.28	.005	1.66	1.13	2.44	.009	.53	.21	1.34	.18
Stage 1	1.0 (Ref)				1.0 (Ref)				1.0 (Ref)
2	2.51	1.90	3.33	< .001	2.55	1.88	3.46	< .001	1.48	.73	2.97	.28
3	7.10	5.05	9.97	< .001	7.56	5.18	11.02	< .001	5.49	2.17	13.87	< .001
missing	3.69	2.42	5.63	< .001	2.55	1.54	4.21	< .001	1.60	.46	5.57	.46
Grade 1	1.0 (Ref)				1.0 (Ref)				1.0 (Ref)
2	1.80	1.27	2.54	.001	1.12	.77	1.62	.55	3.28	1.29	8.35	.01
3	2.63	1.84	3.76	< .001	2.39	1.65	3.46	< .001	4.08	1.55	10.79	.005
missing	1.84	1.21	2.78	.004	1.391	.87	2.22	.17	2.11	.64	6.92	.22
ER negative	1.0 (Ref)				1.0 (Ref)				1.0 (Ref)
positive	.63	.48	.84	.002	.61	.44	.83	.002	.59	.27	1.26	.17
missing	.65	.46	.91	.01	.58	.40	.84	.003	.90	.36	2.25	.82
Age	1.02	1.01	1.03	.001	1.00	.99	1.02	.54	1.01	.98	1.04	.70

ISSN: 1465-542X